Billy W. Loo, Jr., MD, PhD, DABR

Clinical Focus

• Cancer> Head and Neck Cancer
• Cancer> Radiation Oncology
• Cancer> Radiation Oncology> Lung Cancer
• Radiation Oncology
• Radiation Therapy

Administrative Appointments

• Co-Chair, New Technologies Committee, Radiation Oncology (2011 - present)
• Thoracic Radiation Oncology Program Leader, Radiation Oncology (2005 - present)

Honors and Awards

• Henry S. Kaplan Memorial Prize for Teaching in Radiation Oncology, Stanford University (2009)
• Young Investigator Travel Grant, ECOG (2005)
• Basic Science Travel Grant, ASTRO (2005)
• Roentgen Resident/Fellow Research Award, RSNA (2004)
• Travel Grant Award, Best of ASCO Meeting, Denver, ASCO (2004)

Professional Education

Postdoctoral Advisees

Frederick Lartey

Graduate & Fellowship Program Affiliations

• Radiation Oncology

Internet Links

• Dr. Loo's Home Page

Current Research Interests

My main clinical specialties are radiation treatment of lung cancer and head & neck cancer, and I serve as the Thoracic Radiation Oncology Program Leader.

My clinical research interests include 4-D multimodality imaging of tumor and organ motion using CT, PET, and MR; novel functional/metabolic imaging of tumor hypoxia and lymphatic drainage; and implementation and clinical trials of high-precision image-guided radiation therapy including 4-D IMRT, dynamic conformal arc radiotherapy (DCART) and volumetric modulated arc therapy (VMAT), and stereotactic ablative radiotherapy (SABR). My preclinical and translational research interests include novel functional imaging of inflammation as a mechanism of late normal tissue radiation injury, novel reconstruction and processing methods for 4-D imaging data to reduce artifacts and extract functional/physiologic information, and the radiobiology of tumor hypoxia and SABR.

Clinical Trials

• 4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy Recruiting
• Imaging and Biomarkers of Hypoxia in Solid Tumors Recruiting
• Phase I Accelerated Hypofractionated IGRT in Stage II-IV NSCLC and Poor Performance Status Recruiting
• Phase II trial of Individualized Lung Tumor Stereotactic Ablative Radiotherapy (SABR) Recruiting
• Pulmonary Interstitial Lymphography in Early Stage Lung Cancer Recruiting

Publications

• Interim-treatment Quantitative PET Parameters Predict Progression and Death Among Patients with Hodgkin's Disease. Tseng D, Rachakonda LP, Su Z, Advani R, Horning S, Hoppe RT, Quon A, Graves EE, Loo BW, Tran PT. Radiat Oncol. 2012; 7 (1): 5
• Intrafraction Verification of Gated RapidArc by Using Beam-Level Kilovoltage X-Ray Images. Li R, Mok E, Chang DT, Daly M, Loo BW, Diehn M, Le QT, Koong A, Xing L. Int J Radiat Oncol Biol Phys. 2012
• Malignant pleural mesothelioma. Clinical practice guidelines in oncology. Ettinger DS, Akerley W, Borghaei H, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Schenck MP, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC. J Natl Compr Canc Netw. 2012; 10 (1): 26-41
• Metabolic Tumor Volume is an Independent Prognostic Factor in Patients Treated Definitively for Non-Small-Cell Lung Cancer. Lee P, Bazan JG, Lavori PW, Weerasuriya DK, Quon A, Le QT, Wakelee HA, Graves EE, Loo BW. Clin Lung Cancer. 2012; 13 (1): 52-8
• Postchemoradiotherapy Positron Emission Tomography Predicts Pathologic Response and Survival in Patients with Esophageal Cancer. Jayachandran P, Pai RK, Quon A, Graves E, Krakow TE, La T, Loo BW, Koong AC, Chang DT. Int J Radiat Oncol Biol Phys. 2012